Danaher (NYSE:DHR) Profitability Rank

: 8 (As of Sep. 2023)

View and export this data going back to 1986. Start your Free Trial

Danaher has the Profitability Rank of 8. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Danaher's Operating Margin % for the quarter that ended in Sep. 2023 was 20.92%. As of today, Danaher's Piotroski F-Score is 4.

Competitive Comparison

For the Diagnostics & Research subindustry, Danaher's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Danaher Profitability Rank Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Danaher's Profitability Rank falls into.

Danaher Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Danaher has the Profitability Rank of 8. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Danaher's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	1438	/	6873
	=	20.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Danaher has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

Danaher Corp operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank

Danaher Profitability Rank Related Terms

Thank you for viewing the detailed overview of Danaher's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Danaher (NYSE:DHR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Profitability Rank

Comparable Companies

Traded in Other Exchanges

DHR:Mexico DAPd:UK DAP:Germany DAP:Germany DAP:Germany DHER34:Brazil DHRC:Austria

Address

2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, USA, 20037-1701

Website

https://www.danaher.com

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in two segments--life sciences and diagnostics--after the late 2023 divesititure of its environmental and applied solutions group, Veralto.

Executives

Feroz Dewan	director	C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Georgeann Couchara	officer: SVP, Human Resources	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Christopher Bouda	officer: VP, Chief Accounting Officer	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
A Shane Sanders	director	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Jennifer Honeycutt	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jose-carlos Gutierrez-ramos	officer: SVP, Chief Scientific Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Pardis C Sabeti	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jessica L Mega	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew	officer: EVP & Chief Financial Officer	2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Joakim Weidemanis	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Steven M Rales	director, officer: Chairman	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Raymond C Stevens	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Rainer Blair	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Brian W Ellis	officer: Senior Vice President - GC	2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037